An Single-blind, Multi-center, Randomization, Phase Ⅱ Study to Evaluate Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-derived Mesenchymal Stem Cells) in Erectile Dysfunction Patients With Following Radical Prostatectomy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous mesenchymal stem cell therapy Pharmicell (Primary)
Indications Erectile dysfunction
Focus Therapeutic Use
Acronyms Cellgram-ED
Sponsors Pharmicell

Most Recent Events

10 Apr 2024 Planned End Date changed from 31 Oct 2023 to 31 Jan 2026.
10 Apr 2024 Planned primary completion date changed from 31 Oct 2023 to 31 Dec 2025.
07 Nov 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Oct 2020).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight